Clinical trials
catalyst calendar across sponsors →Studies where APGE is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
4 interventional
Held by 18 tracked-famous managers (Balyasny Asset Management L.P., MILLENNIUM MANAGEMENT LLC, Qube Research & Technologies Ltd, SOROS FUND MANAGEMENT LLC, Man Group plc, +13 more) · FINRA short interest 4.0 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 9 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic DermatitisNCT07003425Number of Participants with Treatment Emergent Adverse EventsNon-randomized · Quadruple-masked · Treatment | Phase 2 | Recruiting | Drug: APG777, APG777, APG777 | Atopic Dermatitis | 350 | Dec 2029 | ≤ 1,230 d | 2026-07-29 |
| An Active Comparator Safety Study Evaluating the Combination of APG777 + APG990 in Moderate-to-Severe Atopic DermatitisNCT07027527Number of Participants with Treatment Emergent Adverse Events (TEAEs)Randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: APG777, APG990, Dupilumab | Atopic Dermatitis | 86 | Dec 2026 | ≤ 134 d | 2026-06-08 |
| A Study Evaluating APG777 in Atopic DermatitisNCT06395948Part A: Percent Change From Baseline in Eczema Area and Severity Index (EASI)Randomized · Quadruple-masked · Treatment | Phase 2 | Active, not recruiting | Drug: APG777, Placebo | Atopic Dermatitis | 470 | Nov 2026 | ≤ 103 d | 2026-07-22 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Immunogenicity of APG777 in Adults With AsthmaNCT06920901Number of Participants with Treatment Emergent Adverse Events (TEAEs)Randomized · Triple-masked · Treatment | Phase 1 | Active, not recruiting | Drug: APG777, Placebo | Asthma | 31 | Sep 2026 | ≤ 42 d | 2026-02-17 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19